🔎 Trials Near Me

Utama › Penyakit Paru Interstisial › Missouri

Kajian klinikal Penyakit Paru Interstisial di Missouri

6 kajian untuk Penyakit Paru Interstisial sedang mencari peserta di lokasi di Missouri.

Bandar di Missouri

Teks kajian rasmi (Bahasa Inggeris)

A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

  • GSK Investigational Site, St Louis
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT06572384

A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

  • The Lung Research Center, LLC, Chesterfield
Mengambil pesertaFasa 2
Umur 40 ke atas · Semua jantina · Dikemas kini 4 Sep 2026 · NCT06968845

Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

  • Hannibal Regional Healthcare System, Hannibal
  • Mercy Hospital Springfield, Springfield
Mengambil peserta
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Sep 2026 · NCT06911632

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

  • Washington University School of Medicine, St Louis
Mengambil pesertaKajian pemerhatian
Umur 18 ke atas · Semua jantina · Dikemas kini 26 Ogo 2026 · NCT06388421

Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry

  • Washington University, St Louis
Mengambil pesertaKajian pemerhatian
Umur 21 ke atas · Semua jantina · Dikemas kini 12 Ogo 2026 · NCT01915511

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

  • The Lung Research Center, LLC, Chesterfield
  • Saint Luke's Hospital of Kansas City, Kansas City
  • Washington University School of Medicine, St Louis
Mengambil pesertaFasa 3
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Jul 2026 · NCT05943535

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.